$AMRN upside targets, High risk , high reward

• 
  

MAy be a case that speculators are in the stock for a quick $$$ after a very erratic selloff.
Jefferies analyst Michael Yee is hosting a conference call with life sciences patent lawyer Jacob Sherkow, who said during the call that he believes Amarin has a 50% chance to win its appeal related to its recent loss in litigation related to generic versions of Vascepa.
Source TheFly.com